ANI Pharmaceuticals Continues Strong Market Presence with FDA Approval and Launch of New Generic Medications
Princeton, N.J. July 02, 2024’ - ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), a leading U.S. specialty pharmaceutical company, has announced the FDA approval of its Abbreviated New Drug Application (ANDA) for Naproxen Delayed-Release Tablets, USP. The newly approved drug is the generic version of the reference listed drug (RLD) EC-Naprosyn®. This significant milestone further strengthens ANI Pharmaceuticals’ already robust portfolio of generic medications.
The introduction of Naproxen Delayed-Release Tablets marks the third major product launch by ANI Pharmaceuticals in 2024, following the strategic launches of Baclofen Oral Suspension and Levofloxacin Oral Solution, USP, earlier in the year.
Naproxen Delayed-Release Tablets, USP: A Significant Addition to Pain Management’
Naproxen is a widely used nonsteroidal anti-inflammatory drug (NSAID) commonly prescribed for pain relief and inflammation management. The delayed-release formula is particularly beneficial for patients needing prolonged relief without frequent dosing. By offering a generic version of EC-Naprosyn®, ANI Pharmaceuticals aims to provide affordable medication options to patients, contributing to better health outcomes while minimizing healthcare costs.
Strategic Product Launches in 2024’
In addition to the recent approval and launch of Naproxen Delayed-Release Tablets, ANI Pharmaceuticals made notable strides in the generic medication market earlier in the year:
April 09, 2024: Launch of Baclofen Oral Suspension’
On April 9, 2024, ANI Pharmaceuticals announced the market introduction of Baclofen Oral Suspension, a generic counterpart to the RLD Fleqsuvy®. Baclofen is primarily used to treat muscle spasticity by acting on the central nervous system. The launch of this product underscores ANI’s commitment to expanding its range of neurological disorder treatments. The oral suspension form also provides an essential option for patients requiring flexibility in dosage and those who may have difficulties swallowing tablets.
March 27, 2024: Launch of Levofloxacin Oral Solution, USP’
Earlier this year, on March 27, 2024, ANI Pharmaceuticals introduced Levofloxacin Oral Solution, a generic version of Levaquin®. Levofloxacin is a potent antibiotic used to treat a variety of bacterial infections. According to the latest estimates from IQVIA/IMS Health, the annual U.S. market for Levofloxacin Oral Solution is approximately $7.1 million. The introduction of a cost-effective generic version aims to boost accessibility for patients and healthcare providers.
A Year of Growth and Expansion’
These product launches represent ANI Pharmaceuticals’ strategic focus on diversifying its portfolio and addressing various therapeutic areas. By continually bringing high-quality, cost-effective generic medications to market, ANI maintains its reputation as a dynamic player in the pharmaceutical industry.
Arthur Przybyl, President and CEO of ANI Pharmaceuticals, commented, Our recent launches of Naproxen Delayed-Release Tablets, Baclofen Oral Suspension, and Levofloxacin Oral Solution are testaments to our ongoing dedication to broadening patient access to essential medications. Each product launch highlights our commitment to meeting the evolving needs of the healthcare market while providing value-driven solutions.
Conclusion’
ANI Pharmaceuticals’ successful FDA approval and subsequent launches reflect the company’s expertise in bringing critical medications to market efficiently. As the healthcare landscape continues to evolve, ANI remains poised to adapt and grow, ensuring that patients and healthcare providers have access to high-quality, affordable treatments.
Comments